Isolongifolene [1135-66-6]

Cat# HY-N7363-50mg

Size : 50mg

Marca : MedChemExpress


Description

Isolongifolene ((-)-Isolongifolene) is a tricyclic sesquiterpene isolated from Murraya koenigii. Isolongifolene attenuates Rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of PI3K/AKT/GSK-3β signaling pathways. Isolongifolene has antioxidant, anti-inflammatory, anticancer and neuroprotective properties[1].

In Vitro

Isolongifolene (0-50 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment significantly alleviates Rotenone-induced cytotoxicity in SH-SY5Y cells in a dose-dependent manner[1].
Isolongifolene (10 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment attenuates Rotenone-induced apoptosis in SH-SY5Y cells[1].
Isolongifolene (10 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment attenuates Rotenone induced toxicity by down-regulating Bax, caspases-3, 6, 8 and 9 expression and up-regulating of Bcl-2 expression. Furthermore regulation of p-P13K, p-AKT and p-GSK-3β expression by Isolongifolene[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: SH-SY5Y neuroblastoma cells
Concentration: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM and 50 µM
Incubation Time: 26 hours
Result: Significantly alleviated Rotenone-induced cytotoxicity in SH-SY5Y cells.

Apoptosis Analysis[1]

Cell Line: SH-SY5Y neuroblastoma cells
Concentration: 10 µM
Incubation Time: 26 hours
Result: Attenuated Rotenone-induced apoptosis in SH-SY5Y cells.

Western Blot Analysis[1]

Cell Line: SH-SY5Y neuroblastoma cells
Concentration: 10 µM
Incubation Time: 26 hours
Result: Attenuated rotenone induced toxicity by down-regulating Bax, caspases-3, 6, 8 and 9 expression and up-regulating of Bcl-2 expression. Prevented the rotenone-induced decreased phosphorylation of GSK-3β.
Masse moléculaire

204.35

Formule

C15H24

CAS No.
Appearance

Liquid (Density: 0.930 g/cm3)

Color

Colorless to light yellow

SMILES

CC1(C)[C@]23CC[C@](C3)(21)C(C)(C)C2=CCC1

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 10 mg/mL (48.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8936 mL 24.4678 mL 48.9356 mL
5 mM 0.9787 mL 4.8936 mL 9.7871 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 1 mg/mL (4.89 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 1 mg/mL (4.89 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références